A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Cord serum metabolic signatures of future progression to immune-mediated diseases




TekijätHyötyläinen Tuulia, Karthikeyan Bagavathy S., Ghaffarzadegan Tannaz, Triplett Eric W., Orešič Matej, Ludvigsson Johnny

KustantajaElsevier Inc.

Julkaisuvuosi2023

JournaliScience

Tietokannassa oleva lehden nimiiScience

Vuosikerta26

Numero3

ISSN2589-0042

eISSN2589-0042

DOIhttps://doi.org/10.1016/j.isci.2023.106268(external)

Verkko-osoitehttps://www.sciencedirect.com/science/article/pii/S2589004223003450?via%3Dihub(external)

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/179267340(external)


Tiivistelmä

Previous prospective studies suggest that progression to autoimmune diseases is preceded by metabolic dysregulation, but it is not clear which metabolic changes are disease-specific and which are common across multiple immune-mediated diseases. Here we investigated metabolic profiles in cord serum in a general population cohort (All Babies In Southeast Sweden; ABIS), comprising infants who progressed to one or more immune-mediated diseases later in life: type 1 diabetes (n = 12), celiac disease (n = 28), juvenile idiopathic arthritis (n = 9), inflammatory bowel disease (n = 7), and hypothyroidism (n = 6); and matched controls (n = 270). We observed elevated levels of multiple triacylglycerols (TGs) an alteration in several gut microbiota related metabolites in the autoimmune groups. The most distinct differences were observed in those infants who later developed HT. The specific similarities observed in metabolic profiles across autoimmune diseases suggest that they share specific common metabolic phenotypes at birth that contrast with those of healthy controls.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2025-27-03 at 21:50